한국간담췌외과학회지 (Annals of Hepato-Biliary-Pancreatic Surgery)

  • 제26권3호
  • /
  • Pages.235-243
  • /
  • 2022
  • /
  • 2508-5778(pISSN)
  • /
  • 2508-5859(eISSN)
한국간담췌외과학회 (The Korean Association of Hepato-Biliary-Pancreatic Surgery)
권호 표지
DOI QR코드

DOI QR Code

Changing incidence and survival of intrahepatic cholangiocarcinoma based on Surveillance, Epidemiology, and End Results Database (2000-2017)

  • Hassam Ali (Department of Internal Medicine, East Carolina University/Vidant Medical Center) ;
  • Brandon Tedder (Department of Internal Medicine, East Carolina University/Vidant Medical Center) ;
  • Syed Hamza Waqar (Department of Internal Medicine, State University of New York) ;
  • Rana Mohamed (Department of Internal Medicine, East Carolina University/Vidant Medical Center) ;
  • Edward Lawson Cate (Department of Internal Medicine, East Carolina University/Vidant Medical Center) ;
  • Eslam Ali (Department of Gastroenterology, East Carolina University/Vidant Medical Center)
  • 투고 : 2021.12.28
  • 심사 : 2022.02.10
  • 발행 : 2022.08.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Backgrounds/Aims: Historically, the incidence and prognosis of patients diagnosed with intrahepatic cholangiocarcinoma (ICC) have been inadequately understood. Survival analysis in ICC has yet to be investigated in a population-based study. Methods: We conducted a retrospective cohort study using the Surveillance, Epidemiology, and End Results Program (SEER) 18 Registry. Risk ratios were estimated via Poisson regression. Hazard ratios for 5-year survival were estimated using hierarchical Cox regression models. Results: Males show a higher rate of age-adjusted ICC incidence. Blacks carried a decreased risk of ICC diagnosis than Whites, while Asians revealed a higher risk of ICC diagnosis when compared with Whites. The observed survival rates at 12, 36, and 60 months were 36.3%, 12.8%, and 8.1%, respectively. Compared with Whites, Blacks showed an increased risk of death (p < 0.01). Lymph node resection during surgery was associated with a 64.1% reduced risk of mortality (p < 0.01). A higher T stage at diagnosis was associated with poor survival (p < 0.01). Surgery combined with chemoradiotherapy, radiotherapy, or chemotherapy was associated with a reduced risk of mortality compared with nonsurgical interventions (p < 0.01). Conclusions: ICC incidence has been increasing since 2000, especially in White males. The risk of ICC rises with age. Lymph node removal is associated with better survival. In recent years, survival had worsened, and surgical intervention improved survival compared with nonsurgical management.

키워드

참고문헌

  1. Zhang H, Yang T, Wu M, Shen F. Intrahepatic cholangiocarcinoma: epidemiology, risk factors, diagnosis and surgical management. Cancer Lett 2016;379:198-205.
  2. Chapman RW. Risk factors for biliary tract carcinogenesis. Ann Oncol 1999;10 Suppl 4:308-311.
  3. Welzel TM, Graubard BI, El-Serag HB, Shaib YH, Hsing AW, Davila JA, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 2007;5:1221-1228.
  4. Dodson RM, Weiss MJ, Cosgrove D, Herman JM, Kamel I, Anders R, et al. Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg 2013;217:736-750.e4.
  5. Welzel TM, McGlynn KA, Hsing AW, O'Brien TR, Pfeiffer RM. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst 2006;98:873-875.
  6. DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007;245:755-762.
  7. Nakeeb A, Tran KQ, Black MJ, Erickson BA, Ritch PS, Quebbeman EJ, et al. Improved survival in resected biliary malignancies. Surgery 2002;132:555-563; discission 563-564.
  8. Hashimoto N, Yachida S, Okano K, Wakabayashi H, Imaida K, Kurokohchi K, et al. Immunohistochemically detected expression of p27(Kip1) and Skp2 predicts survival in patients with intrahepatic cholangiocarcinomas. Ann Surg Oncol 2009;16:395-403.
  9. Surveillance Research Program, NCIs Division of Cancer Control and Population Sciences. SEER Registries [Internet]. Washington, D.C.: National Cancer Institute 2021 [cited 2021 Sep 29]. Available from: https://seer.cancer.gov/.
  10. Surveillance Research Program, National Cancer Institute. SEER*Stat SEER*Stat software version 8.3.9.2 [Internet]. Washington, D.C.: National Cancer Institute 2021 [cited 2021 Sep 29]. Available from: https://seer.cancer.gov/seerstat/.
  11. Deadmond MA, Smith-Gagen JA. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011. J Cancer Res Clin Oncol 2015;141:2131-2138.
  12. Devesa SS, Donaldson J, Fears T. Graphical presentation of trends in rates. Am J Epidemiol 1995;141:300-304.
  13. Tyson GL, Ilyas JA, Duan Z, Green LK, Younes M, El-Serag HB, et al. Secular trends in the incidence of cholangiocarcinoma in the USA and the impact of misclassification. Dig Dis Sci 2014;59:3103-3110.
  14. Ailawadhi S, Aldoss IT, Yang D, Razavi P, Cozen W, Sher T, et al. Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups. Br J Haematol 2012;158:91-98.
  15. Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang Y, et al. Comparison of incidence of intrahepatic and extrahepatic cholangiocarcinoma--focus on East and South-Eastern Asia. Asian Pac J Cancer Prev 2010;11:1159-1166.
  16. Brito AF, Abrantes AM, Encarnacao JC, Tralhao JG, Botelho MF. Cholangiocarcinoma: from molecular biology to treatment. Med Oncol 2015;32:245.
  17. Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 2008;10:77-82.
  18. Bonnie RJ, Ford MA, Phillips JK. Trends in opioid use, harms, and treatment. In: Bonnie RJ, Ford MA, Phillips JK, ed. Pain management and the opioid epidemic: balancing societal and individual benefits and risks of prescription opioid use. Washington, D.C.: National Academies Press, 2017:187-266.
  19. Toy E, Balasubramanian S, Selmi C, Li CS, Bowlus CL. The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population. BMC Gastroenterol 2011;11:83.
  20. Gupta A, Dixon E. Epidemiology and risk factors: intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2017;6:101-104.
  21. Mody K, Antwi SO, Hodge DO, Ailawadhi S, Roberts L, BekaiiSaab T. A SEER-based multi-ethnic picture of advanced intrahepatic cholangiocarcinoma in the United States pre- and post-the advent of gemcitabine/cisplatin. J Gastrointest Oncol 2018;9:1063-1073.
  22. Haider AH, Scott VK, Rehman KA, Velopulos C, Bentley JM, Cornwell EE 3rd, et al. Racial disparities in surgical care and outcomes in the United States: a comprehensive review of patient, provider, and systemic factors. J Am Coll Surg 2013;216:482-492.e12.
  23. Spolverato G, Vitale A, Cucchetti A, Popescu I, Marques HP, Aldrighetti L, et al. Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma? Cancer 2015;121:3998-4006.
  24. Hartog H, Ijzermans JN, van Gulik TM, Groot Koerkamp B. Resection of perihilar cholangiocarcinoma. Surg Clin North Am 2016;96:247-267.
  25. Gurusamy KS, Li J, Vaughan J, Sharma D, Davidson BR. Cardiopulmonary interventions to decrease blood loss and blood transfusion requirements for liver resection. Cochrane Database Syst Rev 2012;2012:CD007338.